蒋海英

    【摘要】? 目的? 探讨曲妥珠单抗与帕妥珠单抗双靶向联合化疗药物治疗人表皮生长因子受体2(HER-2)阳性乳腺癌的临床效果。方法? 选择2018年3月- 2023年6月六盘水市人民医院收治的72例HER-2阳性乳腺癌患者，根据组间基线资料均衡可比的原则，按随机数字表法分成两组，每组36例。两组患者均采取多西他赛联合卡铂治疗，在此基础上对照组加曲妥珠单抗治疗7个疗程，观察组则应用曲妥珠单抗与帕妥珠单抗双靶向联合治疗7个疗程。对比两组患者的临床疗效、治疗前后血清指标[糖类抗原125(CA-125)、糖类抗原153(CA-153)]水平及治疗期间不良反应情况。结果? 观察组患者的治疗有效率(80.55%)显著高于对照组(50.00%)，组间差异有统计学意义(P0.05)；治疗7个疗程后，两组患者CA-125、CA-153血清指标水平均降低，但观察组低于对照组，差异有统计学意义(P0.05)。结论? 对于HER-2阳性乳腺癌，采取曲妥珠单抗与帕妥珠单抗双靶向联合化疗药物治法，治疗效果好，显著降低血清CA-125、CA-153水平，同时不增加不良反应发生率。

    【关键词】? 人表皮生长因子受体2；乳腺癌；化疗；曲妥珠单抗；帕妥珠单抗

    中图分类号? R737.9? ?文献标识码? A? ? 文章编号? 1671-0223(2024)13--03

    Application of trastuzumab and parstuzumab double targeted chemotherapy in human epidermal growth factor receptor 2 positive breast cancer? Jiang Haiying. Department of Oncology and Hematology， Liupanshui People's Hospital， Liupanshui 553000， China

    【Abstract】? Objective To investigate the clinical effect of trastuzumab and patouzumab combined with chemotherapy in the treatment of human epidermal growth factor receptor 2 (HER-2) positive breast cancer. Methods? ?A total of 72 HER-2 positive breast cancer patients admitted to Liupanshui People's Hospital from March 2018 to June 2023 were selected. According to the principle of balanced and comparable baseline data between groups ......